NEW YORK (GenomeWeb News) – Genomics services firm BioServe will use biosamples from Philadelphia's Fox Chase Cancer Center to supplement its Global Repository under an exclusive two-year agreement, the Beltsville, Md.-based company said.

The agreement is part of an effort to plug up a "shortage of clinical quality biomaterials" for use in genetic and biomarker-focused cancer research that has caused a bottleneck in biotechnology research, BioServe said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.